Mangalam Drugs & OrganicsNSE:MANGALAM -1.32%43 Gross Margin % is 29.91% as of Mar. 2026, which is 0% below its 10-year median of 29.97. GuruFocus rates NSE:MANGALAM with a GF Score™ of 43/100 and a GF Value™ of ₹64.85 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 935 Drug Manufacturers companies, Mangalam Drugs & Organics ranks worse than 78.29% on this metric.
NSE:MANGALAM's Gross Margin % is ranked worse than 78.29% of 935
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:MANGALAM: 31.70
Mangalam Drugs & Organics had a gross margin of 29.91% for the quarter that ended in Mar. 2026 => Competition eroding margins
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Mangalam Drugs & Organics had a gross margin of 29.91% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Mangalam Drugs & Organics Gross Margin % Related Terms
Mangalam Drugs & Organics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MANGALAM vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mangalam Drugs & Organics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mangalam Drugs & Organics Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mangalam Drugs & Organics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Mangalam Drugs & Organics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Mangalam Drugs & Organics (NSE:MANGALAM) has a Gross Margin % of 29.91% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Mangalam Drugs & Organics and its competitors. This is near median its historical median of 29.97. Over the past decade, Mangalam Drugs & Organics' Gross Margin % has ranged from 26.96 to 47.30. According to the industry distribution chart, Mangalam Drugs & Organics ranks #732 out of 935 companies in the Drug Manufacturers industry, placing it in the top 78.3%.
Is Mangalam Drugs & Organics' Gross Margin % too high?
Mangalam Drugs & Organics' current Gross Margin % of 29.91% is near median its 10-year median of 29.97. Over the past 10 years, this metric has ranged from a low of 26.96 to a high of 47.30. The Drug Manufacturers industry median Gross Margin % is 48.54. Mangalam Drugs & Organics' value of 29.91% is 38.4% below this industry median. Based on the distribution chart, Mangalam Drugs & Organics ranks #732 out of 935 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mangalam Drugs & Organics has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mangalam Drugs & Organics ranks #732 out of 935 companies for Gross Margin %. This places Mangalam Drugs & Organics in the lower half of its industry. The industry median Gross Margin % is 48.54. Mangalam Drugs & Organics' value of 29.91% is 38.4% below this benchmark. Historically, Mangalam Drugs & Organics' own Gross Margin % has ranged from 26.96 to 47.30 over the past decade. While the company's 10-year median is 29.97 vs. the industry median of 48.54, Mangalam Drugs & Organics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mangalam Drugs & Organics's current Gross Margin % of 29.91% is 38.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Mangalam Drugs & Organics and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mangalam Drugs & Organics's current Gross Margin % is 29.91%, which is near median its own 10-year median of 29.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹64.85, compared to a current price of ₹28.41 — trading 56.2% below its estimated fair value. The current Gross Margin % is 29.91%, which is near median its 10-year median of 29.97 and 38.4% below the Drug Manufacturers industry median of 48.54. Mangalam Drugs & Organics' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current Gross Margin % is 29.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?
Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued.
The current stock price of ₹28.41 is trading 56.2% below its estimated GF Value™ of ₹64.85.
GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.
Key valuation signals for NSE:MANGALAM:
Gross Margin %: 29.91% (near median its 10-year median of 29.97)
GF Value™: ₹64.85 vs. price of ₹28.41 (56.2% below fair value)
Industry Position: 38.4% below the Drug Manufacturers median (#732 of 935)
No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
43GF Score
Get the complete analysis for NSE:MANGALAM
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MANGALAM has been successfully added to your 
